Publication:
PATTERNS OF CARE FOR LUNG CANCER IN RADIATION ONCOLOGY DEPARTMENTS OF TURKEY

dc.contributor.authorsDemiral, Ayse Nur; Alicikus, Zuemre Arican; Ugur, Vahide Isil; Karadogan, Ilker; Yoeney, Adnan; Andrieu, Meltem Nalca; Yalman, Deniz; Pak, Yuecel; Aksu, Gamze; Oezyigit, Goekhan; Oezkan, Luetfi; Kilciksiz, Sevil; Koca, Sedat; Caloglu, Murat; Yavuz, Ali Aydin; Caglar, Hale Basak; Beyzadeoglu, Murat; Igdem, Sefik; Serin, Meltem; Kaplan, Buenyamin; Koc, Mehmet; Korkmaz, Esra; Karakoyun-Celik, Oemuer; Dincer, Selvi; Kinay, Muenir
dc.date.accessioned2022-03-12T16:00:34Z
dc.date.accessioned2026-01-11T17:43:02Z
dc.date.available2022-03-12T16:00:34Z
dc.date.issued2008
dc.description.abstractPurpose: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. Methods and Materials: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. Results: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were >= IB disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. Conclusion: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach. (c) 2008 Elsevier Inc.
dc.identifier.doi10.1016/j.ijrobp.2008.03.035
dc.identifier.eissn1879-355X
dc.identifier.issn0360-3016
dc.identifier.pubmed18707825
dc.identifier.urihttps://hdl.handle.net/11424/224703
dc.identifier.wosWOS:000261214600037
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPatterns of care
dc.subjectLung cancer
dc.subjectRadiation oncology
dc.subjectRadiotherapy
dc.subjectChemotherapy
dc.subjectTHORACIC RADIOTHERAPY
dc.subjectPOSTOPERATIVE RADIOTHERAPY
dc.subjectRANDOMIZED-TRIAL
dc.subjectCONCURRENT CHEMOTHERAPY
dc.subjectSURVEY PCS
dc.subjectPHASE-III
dc.subjectCARCINOMA
dc.subjectTHERAPY
dc.subjectBRACHYTHERAPY
dc.subjectCISPLATIN
dc.titlePATTERNS OF CARE FOR LUNG CANCER IN RADIATION ONCOLOGY DEPARTMENTS OF TURKEY
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage1537
oaire.citation.issue5
oaire.citation.startPage1530
oaire.citation.titleINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
oaire.citation.volume72

Files